Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iCare 2: Personalized Genomic Treatment for MDS
NCT03446638Phase 2Withdrawn
- Sponsor
- University of Florida
- Start
- May 2019
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS) (2 arms), sponsored by University of Florida. Primary endpoint: Overall Response Rate at 4 months. Planned start May 2019; status: withdrawn.
02
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03446638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446638.